Can-Fite BioPharma Ltd. (NYSE American: CANF)
Investing - Small-Cap Market Intelligence • 5m 0s
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical-stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date
Up Next in Investing - Small-Cap Market Intelligence
-
Ethema Health: New Paradigm in Mental...
Ethema Health Corporation (OTCQB: GRST) operates in the behavioral healthcare space, specifically in the treatment of substance-use disorders. The company has developed a unique treatment model that has shown to be highly effective at treating opioid addiction. Launched in 2011, Ethema plans to o...
-
Cyclo Therapeutics (CTDH)
Cyclo Therapeutics (CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare...
-
Developing Innovative Treatments for ...
Cyclo Therapeutics (CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare...
